Log In
Print this Print this

CTL019 (formerly CART-19)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionAutologous T cells loaded with a lentiviral vector expressing CART-19, which consists of a cancer antigen-binding domain targeting CD19 linked to CD3zeta/CD137 immunostimulatory domains
Molecular Target CD19
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Lentivirus

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today